Envoy Medical, Inc. current report, 28 February 2023

全文

Business Context and Reporting Period

This Form 8-K, filed March 2, 2023, reports actions taken by Anzu Special Acquisition Corp I on February 28, 2023. The filing extends the deadline for completing an initial business combination and reports related stockholder votes and redemptions. The submitted metadata identifies Envoy Medical, Inc., but the filing’s registrant is Anzu Special Acquisition Corp I.

Key Financial and Capital Metrics

  • Trust Account: Approximately $387.5 million was withdrawn to fund redemptions, leaving approximately $45.2 million in the Trust Account.
  • Redemption price: Approximately $10.15 per redeemed Public Share.
  • Shares redeemed: 38,187,226 Public Shares.
  • Remaining Public Shares: 4,312,774 after the redemptions.
  • Revenue, profit, cash flow, margins, and debt: The filing text does not provide clear values for these operating or financial statement metrics.

Material Changes Versus the Prior Comparable Period

  • The initial business combination deadline was extended from March 4, 2023 to September 30, 2023, or an earlier date determined by the Board.
  • Redemptions substantially reduced the Public Share count and Trust Account balance.
  • The filing does not provide a prior-period income statement or cash flow comparison.

Guidance, Outlook, Risks, and Unusual Items

  • The extension provides additional time to complete an initial business combination, but no transaction completion or target-company terms are disclosed in this filing.
  • Completion remains subject to the Company’s ability to consummate a business combination by the revised deadline, unless the Board selects an earlier date.
  • The large redemption represents a material reduction in available Trust Account funds and public shares, which may affect transaction financing and shareholder structure.
  • Stockholders approved the extension proposal with 36,753,901 votes for, 6,216,334 against, and no abstentions. Approval required at least 65% of outstanding Common Stock.
  • 42,970,235 shares, or 80.89% of issued and outstanding Common Stock, were represented at the meeting.
  • The adjournment proposal was approved, but no adjournment was made because the extension proposal passed.

Facts Investors Should Verify

  1. Whether Anzu completed an initial business combination by September 30, 2023 or an earlier Board-selected date.
  2. The final amount remaining in the Trust Account after redemptions, fees, and other adjustments.
  3. The financing and ownership implications of the reduced Public Share count.
  4. Any subsequent filings describing a business combination, liquidation, further extension, or additional redemptions.
  5. The relationship, if any, between Anzu Special Acquisition Corp I and Envoy Medical, Inc., as the filing itself identifies Anzu as the registrant.